Levofloxacin prophylaxis for pediatric leukemia patients: Longitudinal follow‐up for impact on health care‐associated infections
Pediatric Blood & Cancer2022Vol. 69(7), pp. e29525–e29525
Citations Over TimeTop 16% of 2022 papers
Andrea L. Davis, Alexandra M. Stevens, Julienne Brackett, Lucila Marquez, Catherine Foster, Hannah E. Sauer, Judith Campbell
Abstract
Following implementation of a levofloxacin prophylaxis guideline, we observed a significant decrease in BSIs due to Gram-negative rods and NHSN CLABSIs. Vigilant monitoring of outcomes post guideline implementation is critical to track emergence of resistant organisms.
Related Papers
- → Impact of Fluoroquinolone Prophylaxis on Reduced Infection‐Related Mortality among Patients with Neutropenia and Hematologic Malignancies(2005)128 cited
- → Neutropenia and antibiotics: when, what, how and why?(2023)7 cited
- → Levofloxacin for Antibacterial Prophylaxis in Pediatric Patients With Acute Myeloid Leukemia or Undergoing Hematopoietic Stem Cell Transplantation(2020)8 cited
- → Current Treatment of Febrile Neutropenia(2019)
- → 194. Antibiotic-resistant bloodstream infections in pediatric oncology patients on levofloxacin prophylaxis(2020)